ASCO26: Toni Choueiri, MD, KEYNOTE-654 - Poll - MDSpire

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Toni Choueiri, MD, KEYNOTE-654

  • July 1, 2026

Related Content

Case Report: Decade-delayed thyroid metastasis with cervical lymph node involvement from clear cell renal cell carcinoma: diagnostic pitfalls of cytologic-radiologic discordance

Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis

DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway